InTech uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Oncology » "T-Cell Leukemia - Characteristics, Treatment and Prevention", book edited by Mariko Tomita, ISBN 978-953-51-0996-9, Published: February 20, 2013 under CC BY 3.0 license. © The Author(s).

Chapter 5

Glycan Profiling of Adult T-Cell Leukemia (ATL) Cells with the High Resolution Lectin Microarrays

By Hidekatsu Iha and Masao Yamada
DOI: 10.5772/55386

  1. M Amano, M Setoyama, A Grant, F. A Kerdel, Int J Dermatol. 2011 50 8 915 920Human T-lymphotropic virus 1 (HTLV-1) infection-dermatological implications.

  2. O Andrisani, J. E Dixon, J Biol Chem. 1990 265 3212 3218Identification and purification of a novel 120-kDa protein that recognizes the cAMP-responsive element.

  3. A Bazarbachi, Y Plumelle, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O. J Clin Oncol. 2010 28 4177 4183Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.

  4. P. R Baum, R. B Gayle, rd, Ramsdell F, Srinivasan S, Sorensen RA, Watson ML, Seldin MF, Baker E, Sutherland GR, Clifford KN, et al. EMBO J. 1994 13 3992 4001Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.

  5. A. M Dnistrian, M. K Schwartz, Clin Chem. 1981 27 1737 1739Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients.

  6. T Feizi, Nature. 1985 314 53 57Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens.

  7. M Fujii, T Niki, T Mori, T Matsuda, M Matsui, N Nomura, M Seiki, Oncogene. 1991 6 1023 1029HTLV-1 Tax induces expression of various immediate early serum responsive genes.

  8. J Fujisawa, M Seiki, T Kiyokawa, M Yoshida, Proc Natl Acad Sci U S A. 1985 82 2277 2281Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor.

  9. M Fukuda, Cancer Res. 1996 56 2237 2244Possible roles of tumor-associated carbohydrate antigens.

  10. M. M Fuster, J. D Esko, Nat Rev Cancer. 2005 5 526 242The sweet and sour of cancer: glycans as novel therapeutic targets.

  11. P Gagneux, A Varki, Glycobiology. 1999 9 747 755Evolutionary considerations in relating oligosaccharide diversity to biological function.

  12. R. C Gallo, D Mann, S Broder, F. W Ruscetti, M Maeda, V. S Kalyanaraman, M Robert-guroff, Reitz MS Jr. Proc Natl Acad Sci U S A. 1982 79 5680 5683Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma.

  13. G Gaudray, F Gachon, J Basbous, M Biard-piechaczyk, C Devaux, J. M Mesnard, J Virol. 2002 76 12813 12822The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription.

  14. D. U Gonçalves, F. A Proietti, J. G Ribas, M. G Araújo, S. R Pinheiro, A. C Guedes, A. B Carneiro-proietti, Clin Microbiol Rev. 2010 23 577 589Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

  15. S Hakomori, R Kannagi, J Natl Cancer Inst. 1983 71 231 251Glycosphingolipids as tumor-associated and differentiation markers.

  16. S. R Himes, L. S Coles, R Katsikeros, R. K Lang, M. F Shannon, Oncogene. 1993 8 3189 3197HTLV-1 tax activation of the GM-CSF and G-CSF promoters requires the interaction of NF-kB with other transcription factor families.

  17. Y Hinuma, K Nagata, M Hanaoka, M Nakai, T Matsumoto, K. I Kinoshita, S Shirakawa, I Miyoshi, Proc Natl Acad Sci U S A. 1981 78 6476 680Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

  18. R. O Hynes, A Naba, Cold Spring Harb Perspect Biol. 20124:a004903. Overview of the matrisome--an inventory of extracellular matrix constituents and functions.

  19. M Inose, I Higuchi, K Yoshimine, M Suehara, S Izumo, K Arimura, M Osame, J Neurol Sci. 1992 110 73 78Pathological changes in skeletal muscle in HTLV-I-associated myelopathy.

  20. M Iwanaga, T Watanabe, A Utsunomiya, A Okayama, K Uchimaru, K. R Koh, M Ogata, H Kikuchi, Y Sagara, K Uozumi, M Mochizuki, K Tsukasaki, Y Saburi, M Yamamura, J Tanaka, Y Moriuchi, S Hino, S Kamihira, Yamaguchi K; Joint Study on Predisposing Factors of ATL Development investigators. Blood. 2010Aug;116 1211 1219Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.

  21. R Kannagi, M Izawa, T Koike, K Miyazaki, N Kimura, Cancer Sci. 2004 95 377 384Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis.

  22. H Kawai, S Kashiwagi, Y Sano, T Inui, S Saito, Rinsho Shinkeigaku. 1991 31 648 652HTLV-I associated myelopathy with Hashimoto’s thyroiditis--a report of two cases.

  23. I Kimura, T Tsubota, N Ueda, S Tada, S Yoshimoto, J Sogawa, T Shiraishi, T Tamaki, K Ueno, T Fujita, et al Nihon Kyobu Shikkan Gakkai Zasshi. 1989 27 1074 1081Six cases of HTLV-I associated bronchiolo-alveolar disorder (HABA).

  24. A Kuno, N Uchiyama, K-K. u. n. o S Ebe, Y Takashima, S Yamada, M Hirabayashi, J. Nature Methods, 2005;2 851 856Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. La Grenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Lancet. 1990Infective dermatitis of Jamaican children: a marker for HTLV-I infection.

  25. A Manns, W. A Blattner, Transfusion. 1991 31 67 75The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease.

  26. M Mochizuki, T Watanabe, K Yamaguchi, K Takatsuki, K Yoshimura, M Shirao, S Nakashima, S Mori, S Araki, N Miyata, Jpn J Cancer Res. 1992 83 236 239HTLV-I uveitis: a distinct clinical entity caused by HTLV-I.

  27. K Nakano, T Watanabe, Nihon Rinsho. 2012Apr;70 4 671 5Current status and problems of anti-HTLV-1 drug development.

  28. R Nasr, H El Hajj, Y Kfoury, H De Thé, O Hermine, A Bazarbachi, Viruses. 2011 3 750 769Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

  29. K Nishioka, I Maruyama, K Sato, I Kitajima, Y Nakajima, M Osame, Lancet. 1989Feb 25;1(8635):441 Chronic inflammatory arthropathy associated with HTLV-I.

  30. S Olière, R Douville, A Sze, S. M Belgnaoui, J Hiscott, Cytokine Growth Factor Rev. 2011 22 197 210Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis.

  31. M Osame, K Usuku, S Izumo, N Ijichi, H Amitani, A Igata, M Matsumoto, M Tara, Lancet. 1986 1 8488 1031 1032HTLV-I associated myelopathy, a new clinical entity.

  32. F. A Proietti, A. B Carneiro-proietti, B. C Catalan-soares, E. L Murphy, Oncogene. 2005 24 6058 6068Global epidemiology of HTLV-I infection and associated diseases.

  33. T. W Rademacher, R. B Parekh, R. A Dwek, Annu. Rev. Biochem. 1988 57 785 838Glycobiology.

  34. S Ruben, H Poteat, T. H Tan, K Kawakami, R Roeder, W Haseltine, C. A Rosen, Science. 1988 241 89 92Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product.

  35. I Sanada, F Kawano, A Tsukamoto, T Kiyokawa, Rinsho Ketsueki. 1999 40 51 54Adult T-cell leukemia with elevated serum hyaluronic acid levels paralleling disease activity.

  36. H Sasaki, I Nishikata, T Shiraga, E Akamatsu, T Fukami, T Hidaka, Y Kubuki, A Okayama, K Hamada, H Okabe, Y Murakami, H Tsubouchi, K Morishita, Blood. 2005 105 1204 1213Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia.

  37. Y Satou, J Yasunaga, T Zhao, M Yoshida, P Miyazato, K Takai, K Shimizu, K Ohshima, P. L Green, N Ohkura, T Yamaguchi, M Ono, S Sakaguchi, M Matsuoka, PLoS Pathog. 2011e1001274 HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo.

  38. N Sharon, H Lis, Sci. Am. 1993 268 82 89Carbohydrates in cell recognition.

  39. M Shimoyama, Br J Haematol. 1991 79 428 437Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

  40. S Sonoda, H. C Li, K Tajima, Cancer Sci. 2011 102 295 301Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal.

  41. J. M Sowa, J Rheumatol. 1992 19 316 318Human T lymphotropic virus I, myelopathy, polymyositis and synovitis: an expanding rheumatic spectrum.

  42. K Teshigawara, M Maeda, K Nishino, T Nikaido, T Uchiyama, M Tsudo, Y Wano, J Yodoi, J Mol Cell Immunol. 1985 2 17 26Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression.

  43. A. D Theocharis, S. S Skandalis, G. N Tzanakakis, N. K Karamanos, J Febs, 2010 277 3904 3923Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.

  44. K Tsukasaki, Hematology. 2012Suppl 1:S32 35Adult T-cell leukemia-lymphoma.

  45. K Tsukasaki, O Hermine, A Bazarbachi, L Ratner, J. C Ramos, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. J Clin Oncol. 2009 27 453 459Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

  46. A Varki, Glycobiology. 1993 3 97 130Biological roles of oligosaccharides: All of the theories are correct.

  47. A Varki, J Faseb, 1997 11 248 255Sialic acids as ligands in recognition phenomena.

  48. W. P Van Beek, L. A Smets, P Emmelot, Nature. 1975 253 5491 457 460Changed surface glycoprotein as a marker of malignancy in human leukaemic cells.

  49. Y. L Xu, N Adya, E Siores, Q. S Gao, C. Z Giam, J Biol Chem. 1990 265 20285 20292Cellular factors involved in transcription and Tax-mediated trans-activation directed by the TGACGT motifs in human T-cell leukemia virus type I promoter.

  50. M Yamagishi, K Nakano, A Miyake, T Yamochi, Y Kagami, A Tsutsumi, Y Matsuda, A Sato-otsubo, S Muto, A Utsunomiya, K Yamaguchi, K Uchimaru, S Ogawa, T Watanabe, Cancer Cell. 2012 21 121 135Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers.

  51. S Yamaoka, G Courtois, C Bessia, S. T Whiteside, R Weil, F Agou, H. E Kirk, R. J Kay, A Israël, Cell. 1998 93 1231 1240Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation.

  52. M. L Yeung, J Yasunaga, Y Bennasser, N Dusetti, D Harris, N Ahmad, M Matsuoka, K. T Jeang, Cancer Res. 2008 68 8976 8985Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. US Patent 6,787,364 (2004)